Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of cedirogant (ABBV-157) in moderate to severe psoriasis
jRCT2061210069Phase 2Suspended
- Sponsor
- AbbVie Inc.
- Start
- Apr 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in psoriasis comparing Cedirogant with Placebo (2 arms). Primary endpoint: PASI 75 at Week 16. Started Apr 2022; status: suspended.
02
Drugs
cedirogant
03
Conditions
psoriasis
Beyond the preview
Go deeper on jRCT2061210069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210069.